CONTOURA® Vision Pearls Collection (17 videos)

Replay
Cancel

Your 25-second video preview has ended.

to continue watching, please Log In or Register:


Log in / Register

Chapter 8: Integrating Contoura® Vision into Your Practice— Managing Manifest vs Measured

Channels: Refractive

Mark Lobanoff, MD discusses his reasons for acquiring Contoura® Vision technology and uses specific cases to detail how it improved his ability to treat unique corneal irregularities. The panelists also discuss the relationship between measurements taken using aberrometry and topography.

More Videos from CONTOURA® Vision Pearls


WaveLight® Excimer Laser Systems Important Product Information

This information pertains to all WaveLight® Excimer Laser Systems, including the WaveLight® ALLEGRETTO WAVE®, the ALLEGRETTO WAVE® Eye-Q , and the WaveLight® EX500.

Caution: Federal (U.S.) law restricts the WaveLight® Excimer Laser Systems to sale by or on the order of a physician. Only practitioners who are experienced in the medical mangement and surgical treatment of the cornea, who have been trained in laser refractive surgery (including laser calibration and operation) should use a WaveLight® Excimer Laser System.

Indications: FDA has approved the WaveLight® Excimer Laser systems for use in laser-assisted in situ keratomileusis (LASIK) treatments for:

  • the reduction or elimination of myopia of up to - 12.00 D and up to 6.00 D of astigmatism at the spectacle plane;
  • the reduction or elimination of hyperopia up to + 6.00 D with and without astigmatic refractive errors up to 5.00 D at the spectacle plane, with a maximum manifest refraction spherical equivalent of + 6.00 D;
  • the reduction or elimination of naturally occurring mixed astigmatism of up to 6.00 D at the spectacle plane; and
  • the wavefront-guided reduction or elimination of myopia of up to -7.00 D and up to 3.00 D of astigmatism at the spectacle plane.

©2018 Novartis 05/18 US-WVL-17-E-1518(1)